<DOC>
	<DOCNO>NCT00645320</DOCNO>
	<brief_summary>The purpose study evaluate efficacy tolerability ziprasidone patient successfully complete study ziprasidone treatment psychosis ( Protocol A1281074 ) .</brief_summary>
	<brief_title>A Study Ziprasidone Treatment Psychosis Patients Who Had Already Had Benefits From Ziprasidone Treatment Previous Study</brief_title>
	<detailed_description />
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>Psychotic disorder Completion previous study intramuscular ziprasidone Ability continue oral ziprasidone Concomitant treatment antipsychotic agent within 12 hour prior enrollment ; depot agent , period two week cycle , whichever longer , occur last administration patient 's enrollment . Treatment antidepressant mood stabilizer within seven day prior enrollment ; MAOIs ( monoamine oxidase inhibitor ) moclobemide , period two week ; fluoxetine , five week . Resistance conventional psychotic agent . ( Resistance define failure present therapeutic response acute exacerbation proper attempt treatment market antipsychotic agent two occasion two year prior enrollment study . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>